Cargando…

1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program

BACKGROUND: Left ventricular assist devices (LVADs) are a treatment option for end-stage heart failure, traditionally used as a bridge to a transplant. However, LVADs as a destination therapy is an option for individuals with contraindications for transplant. Infections are a common and devastating...

Descripción completa

Detalles Bibliográficos
Autores principales: Milgrom, Alexander, Collins, Amanda, Grubbs, J Aaron, Derrick, Caroline, Logan, Kristin, Edelson, William, Branham, Stephany, Mardis, Andrew, Martin, Jeffrey, Weissman, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809134/
http://dx.doi.org/10.1093/ofid/ofz360.1114
_version_ 1783461910343057408
author Milgrom, Alexander
Collins, Amanda
Grubbs, J Aaron
Derrick, Caroline
Logan, Kristin
Edelson, William
Branham, Stephany
Mardis, Andrew
Martin, Jeffrey
Weissman, Sharon
author_facet Milgrom, Alexander
Collins, Amanda
Grubbs, J Aaron
Derrick, Caroline
Logan, Kristin
Edelson, William
Branham, Stephany
Mardis, Andrew
Martin, Jeffrey
Weissman, Sharon
author_sort Milgrom, Alexander
collection PubMed
description BACKGROUND: Left ventricular assist devices (LVADs) are a treatment option for end-stage heart failure, traditionally used as a bridge to a transplant. However, LVADs as a destination therapy is an option for individuals with contraindications for transplant. Infections are a common and devastating complication with significant morbidity and mortality. The purpose of this study was to assess the impact of risk factors for LVAD-associated infections in a nontransplant LVAD center. METHODS: All patients with implanted LVADs from 2013–2018 at Prisma Health were screened for inclusion. LVAD-associated infection was defined using INTERMACS criteria. Patient characteristics and device characteristics were evaluated for infection risk. Time to infection and associated mortality were also analyzed. RESULTS: Fifty-four of 138 (39.1%) patients developed an LVAD infection (driveline infection, or bacteremia). Mean time to infection among those who experienced infections was 7.78 months, with a standard deviation of 9.58 months. Table 1 summarizes baseline patient characteristics. HeartWare devices, compared with HeartMate II, were at an increased risk of infections and had a shorter time to infection (Figure 1) (HeartWare vs. HeartMate II, HR 2.12, P = 0.01). Those with a BMI of ≥35 kg/m(2) were found on average to have a number of infections 0.729 greater than those with a BMI < 35 kg/m(2) (P = 0.01). Prealbumin, A1C, and chronic kidney disease (any stage) were not found to be associated with infection. Staphylococcus aureus (21, 18.26%), Pseudomonas aeruginosa (24, 20.87%), and Staphylococcus epidermidis (22, 19.13%) were the most common organisms identified. CONCLUSION: In an LVAD center where the majority of patients received LVAD as destination therapy, infection rates were similar as those receiving LVAD as a bridge to transplant. Modifiable risk factors for infection are areas for future interventions and prevention efforts. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6809134
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68091342019-10-28 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program Milgrom, Alexander Collins, Amanda Grubbs, J Aaron Derrick, Caroline Logan, Kristin Edelson, William Branham, Stephany Mardis, Andrew Martin, Jeffrey Weissman, Sharon Open Forum Infect Dis Abstracts BACKGROUND: Left ventricular assist devices (LVADs) are a treatment option for end-stage heart failure, traditionally used as a bridge to a transplant. However, LVADs as a destination therapy is an option for individuals with contraindications for transplant. Infections are a common and devastating complication with significant morbidity and mortality. The purpose of this study was to assess the impact of risk factors for LVAD-associated infections in a nontransplant LVAD center. METHODS: All patients with implanted LVADs from 2013–2018 at Prisma Health were screened for inclusion. LVAD-associated infection was defined using INTERMACS criteria. Patient characteristics and device characteristics were evaluated for infection risk. Time to infection and associated mortality were also analyzed. RESULTS: Fifty-four of 138 (39.1%) patients developed an LVAD infection (driveline infection, or bacteremia). Mean time to infection among those who experienced infections was 7.78 months, with a standard deviation of 9.58 months. Table 1 summarizes baseline patient characteristics. HeartWare devices, compared with HeartMate II, were at an increased risk of infections and had a shorter time to infection (Figure 1) (HeartWare vs. HeartMate II, HR 2.12, P = 0.01). Those with a BMI of ≥35 kg/m(2) were found on average to have a number of infections 0.729 greater than those with a BMI < 35 kg/m(2) (P = 0.01). Prealbumin, A1C, and chronic kidney disease (any stage) were not found to be associated with infection. Staphylococcus aureus (21, 18.26%), Pseudomonas aeruginosa (24, 20.87%), and Staphylococcus epidermidis (22, 19.13%) were the most common organisms identified. CONCLUSION: In an LVAD center where the majority of patients received LVAD as destination therapy, infection rates were similar as those receiving LVAD as a bridge to transplant. Modifiable risk factors for infection are areas for future interventions and prevention efforts. [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6809134/ http://dx.doi.org/10.1093/ofid/ofz360.1114 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Milgrom, Alexander
Collins, Amanda
Grubbs, J Aaron
Derrick, Caroline
Logan, Kristin
Edelson, William
Branham, Stephany
Mardis, Andrew
Martin, Jeffrey
Weissman, Sharon
1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program
title 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program
title_full 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program
title_fullStr 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program
title_full_unstemmed 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program
title_short 1251. Determinants of Infection at a Nontransplanting Cardiothoracic LVAD Program
title_sort 1251. determinants of infection at a nontransplanting cardiothoracic lvad program
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809134/
http://dx.doi.org/10.1093/ofid/ofz360.1114
work_keys_str_mv AT milgromalexander 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram
AT collinsamanda 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram
AT grubbsjaaron 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram
AT derrickcaroline 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram
AT logankristin 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram
AT edelsonwilliam 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram
AT branhamstephany 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram
AT mardisandrew 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram
AT martinjeffrey 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram
AT weissmansharon 1251determinantsofinfectionatanontransplantingcardiothoraciclvadprogram